Table 1.
Patient demographics and characteristics
| SCN5A+ | SCN5A−BrS+ (N = 39) | Controls (N = 38) | p‐valuea | ||
|---|---|---|---|---|---|
| BrS+ (N = 44) | BrS− (N = 35) | ||||
| Age | 40 ± 16 | 32 ± 18 | 46 ± 13 | 38 ± 14 | .001 b |
| Males | 23 (52%) | 17 (49%) | 26 (67%) | 21 (55%) | .42 |
| Follow‐up (months) | 50 ± 58 | 45 ± 51 | 63 ± 73 | ‐ | .43 |
| Spontaneous type 1 | 16 (36%) | 0 | 16 (41%) | ‐ | <.001 |
| Atrial fibrillation or flutter | 1 (2%) | 6 (15%) | 1 (3%) | 0 | .015 c |
| Symptomatic | 9 (21%) | 7 (20%) | 8 (21%) | 0 | .99 |
| Combined endpoint | 1 (2.3%) | 3 (8.6%) | 1 (2.6%) | 0 | .32 |
| ICD | 19 (43%) | 10 (29%) | 14 (36%) | 0 | .41 |
| Beta‐blocker | 4 (9%) | 4 (11%) | 5 (13%) | 4 (11%) | .96 |
BrS, Brugada syndrome; ICD, implantable cardioverter defibrillator; N, number.
Bold p‐values indicate significant results.
a
The p‐value is calculated between the four groups for age, gender, and beta‐blocker use and between the three disease groups for the other variables.
b
p‐value Tukey post hoc test <.05 between SCN5A +BrS− versus SCN5A−BrS+.
c
p‐value significant between SCN5A +BrS− and both SCN5A +BrS+ and SCN5A−BrS+.